Cite
Kaplonek P, Yao L, Reppe K, et al. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine. 2022;doi: 10.1016/j.vaccine.2021.12.068.
Kaplonek, P., Yao, L., Reppe, K., Voß, F., Kohler, T., Ebner, F., Schäfer, A., Blohm, U., Priegue, P., Bräutigam, M., Pereira, C. L., Parameswarappa, S. G., Emmadi, M., Ménová, P., Witzenrath, M., Hammerschmidt, S., Hartmann, S., Sander, L. E., & Seeberger, P. H. (2022). A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine, . https://doi.org/10.1016/j.vaccine.2021.12.068
Kaplonek, Paulina, et al. "A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae." Vaccine vol. (2022). doi: https://doi.org/10.1016/j.vaccine.2021.12.068
Kaplonek P, Yao L, Reppe K, Voß F, Kohler T, Ebner F, Schäfer A, Blohm U, Priegue P, Bräutigam M, Pereira CL, Parameswarappa SG, Emmadi M, Ménová P, Witzenrath M, Hammerschmidt S, Hartmann S, Sander LE, Seeberger PH. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine. 2022 Jan 13; doi: 10.1016/j.vaccine.2021.12.068. Epub 2022 Jan 13. PMID: 35033388.
Copy
Download .nbib